Two complementary studies reveal how an insufficient supply of energy in macrophages, key immune cells in artery walls, ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback